

CURRICULUM VITAE
GREGG ROUNTREE EURE, M.D., FACS

PERSONAL INFORMATION

Home Address: 1301 Kildeer Court
Virginia Beach, Virginia 23451
EuresVB@aol.com

Work Address: Sentara Medical Group - Urology of Virginia, P.C.
August 1991-Present

Office Address: 1200 First Colonial Road, Suite 100
Virginia Beach, Virginia 23454
(757) 481-3556 Office Phone
(757) 496-3865 Office Fax

Date of Birth: December 1, 1959
Hampton, VA

EDUCATION

1977-1981 University of Virginia, B.A.
Charlottesville, Virginia
(Graduated with High Distinction. GPA 3.6)

1981-1985 Medical College of Virginia
Richmond, Virginia
(Ranked in top third of class)

1985 - 1987 Resident, General Surgery
Medical College of Virginia, Richmond, Virginia

1988 - 1991 Resident, Urology
Eastern Virginia Graduate School of Medicine, Norfolk, Virginia

PROFESSIONAL EXPERIENCES

August, 1991-
Present Sentara Medical Group - Urology of Virginia, P.C.
1200 First Colonial Road, Suite 100
Virginia Beach, Virginia 23454

August, 1991-
Present Eastern Virginia Medical School
Assistant Professor of Urology

January 2005-
Present Research Chairman
Urology of Virginia Research Department

July 1990-
June 1991 Eastern Virginia Medical School
Instructor Urology
Chief Resident, EVMS

July, 1987- June, 1988	Emergency Room Physician Sentara Medical Care Centers Norfolk, Virginia (Part-time)
October, 1986- July, 1987	Emergency Room Physician Coastal Physician Services (Part-time)
May, 1983- July, 1987	Extern Richmond Metropolitan Hospital Richmond, Virginia
December, 1983-1985	Extern Johnston-Willis Hospital Richmond, Virginia

PERSONAL MILESTONES

Medical School Admissions Tour Guide
Big Brother Program
Basketball Coach, Tandem Private High School
Extensive intramural sports involvement
Disneyworld Marathon
Master Sommelier, level 1

HOSPITAL CREDENTIALS

Sentara Virginia Beach General Hospital
Sentara Bayside Hospital
Sentara Leigh Hospital
Sentara Norfolk General
Sentara Virginia Beach Ambulatory Surgery Center
Chesapeake General Hospital
Surgery Center of Chesapeake

HONORS AND ACCREDITATION

2007 Hampton Roads Magazine "Best Doc for Men", Urology
AUA Young Leadership Recipient
Physician's Recognition Award
2003 Hampton Roads Magazine "Best Doc for Men", Urology
Best Surgical Teacher (Awarded by the residents)
Florence Smith Medical Merit Scholarship of the Norfolk Foundation
Chi Psi Graduate Fellowship Award
Member Alpha Epsilon Delta, National Premedical Honor Society
Dean's List UVA, All Semesters

SOCIETIES AND MEMBERSHIPS

American Association of Clinical Urologists
American Medical Association
American Urological Association
Diplomat of the American Board of Urology
Diplomat of the National Board of Medical Examiners
Fellow of the American College of Surgeons
Medical Society of Virginia
Seaboard Medical Association
Society of University Urologists
Tidewater Urological Society
Virginia Beach Medical Society
Virginia Chapter College of Surgeons
Virginia Urological Society

COMMITTEES

Board of Directors, Mid-Atlantic American Urology Association
OR/PAR (Operating Room/Post Anesthesia Recovery) Committee, Sentara Virginia Beach General Hospital
Cancer Committee, Sentara Virginia Beach General Hospital
Surgery Privileges Subcommittee, Sentara Virginia Beach General Hospital
Tumor Board, Presenter, Sentara Virginia Beach General
Member, Board of Directors, Urology of Virginia
Director of Clinical Research, Devine Tidewater Urology
Chairman, Organizational, Development, Marketing Committee, Urology of Virginia
Management Committee, Devine Tidewater Urology
Member, Urology of Virginia Board

CONSULTANT/PRECEPTORSHIPS/TRAINING

Physician trainer for GreenLight, Photoselective Vaporization of Prostate (PVP)
Gerson Lehrman Consultation
Site Evaluator, Boston Scientific Prolieve Microwave System

CERTIFICATIONS

Certified Trainer For GreenLight Photoselective2003
Recertification American Board of Urology 2003
Certified Healthtronics Lithotron Kidney Lithotripter 2001
Certified Trainer for Indigo LaserOptic 1999
Certified Trainer for Scalpelless Vasectomies 1995
American Board of Urology Certification 1995
Certified Candela MDF-2000 Lasertripter 1993
Certified in Extra Corporeal
Shockwave Lithotripsy-Lithostar 1991
Certified in Laser Surgery 1991
National Medical Boards 1986
Advanced Trauma Life Support 1986
Advanced Cardiac Life Support 1984

PROFESSIONAL ACTIVITIES

AUA Health Policy Council
Advisor and Speaker for GSK
Advisor and Speaker for Boehringer Ingelheim: BPH
Advisory Board for Organon
Consultant for Man to Man Prostate Cancer Counseling Program (sponsored through the ACS)
Consultant and Speaker, American Medical Systems
Consultant Astra-Zenica
Consultant, Lilly-ICOS
Consultant, Ortho Urology
Coordinator, Prostate Ultrasound Conference, Dr. William Cooner, SNGH
Program Director and Speaker "Urology Update Conference" , 1998, 2001, 2005
Faculty Leader for Resident Journal Club
Scientific Advisor for Thermatrix: Trans-urethral Microwave Therapy (TUMT) Study
Exam Proctor, Residents In-Service Exam, Eastern Virginia Medical School
Virginia District #2 Advisor, Committee on Applicants for the American College of Surgeons
Secretary/Treasurer, Tidewater Urological Society
President, Tidewater Urological Society
Supervising Physician for Physician Assistant, Devine Tidewater Urology
Supervising Physician for Physician Assistant, Sentara Virginia Beach General and Sentara Bayside
President & Director of the Foundation for Specialized Surgery
Hampton Roads Lithotripsy Board

ACADEMIC APPOINTMENTS

Educational Director for Urology Residency Program at Sentara Virginia Beach General Hospital, 2002-Present
Assistant Professor of Clinical Urology, Eastern Virginia Graduate School of Medicine, Norfolk, Virginia, July 1, 1992- Present
Instructor, Department of Urology, Eastern Virginia Graduate School of Medicine, Norfolk, Virginia, August 1991-July 1992

ACADEMIC PRESENTATIONS

"UTI's", EVMS, Norfolk, VA, October 21, 1992

"The Advances of Urologic Surgery", Sentara Leigh Hospital, December 9, 1992

"UTI's", EVMS, Norfolk, Virginia, October 13, 1993

"Prostate Cancer: Use of Markers, Ultrasound, and Laparoscope", Virginia Chapter, American College of Surgeons, Hot Springs, Virginia, April 29-May 1, 1994

"BPH", Merck Pharmaceutical, Norfolk, Virginia, June 7, 1994

New Advances in BPH and Prostate Cancer, Urology Update for Primary Care Physicians, Virginia Beach, Virginia, October 8, 1994

"BPH Update", Filipino Medical Association, Norfolk, Virginia, July 9, 1995

Management of Kidney Stone Disease, Virginia Beach, Virginia, July 13, 1995

Prostate Cancer and Other Neoplasms of the Genitourinary Tract, February 26-27, 1996

“Current Management Trends in BPH”, Guest Speaker, Maryland Academy of Medicine, Ocean City, MD June 11-12, 1998

“New Treatments for Erectile Dysfunction”, Virginia Beach General Hospital Grand Rounds, August 12, 1998

“Vasectomy and No-Scalpel Technique” Resident Lecture, EVMS, April 29, 1999

“Sexual Vigor”, Anti-aging seminar EVMS, Sentara, March 7, 1998

“Erectile Dysfunction”, WTKR Channel 3 News, April 28, 1998

“BPH”, Guest Speaker Symposium on Urology, Vencor Hospital, Arlington, VA May 9, 1998

“BPH”, Grand Rounds CME Committee, Virginia Beach General Hospital, May 18, 1998

“BPH”, Grand Rounds Virginia Beach General Hospital, May 19, 1998

“Diagnosis and Treatment of Erectile Dysfunction”, Filipino Medical Association, September 21, 1998

“Current Treatment Options for Prostatitis and BPH”, Sentara Bayside Hospital, October 14, 1999

“BPH: Pills, Laser, Cut or Cook”, Urology Update for Primary Care, Virginia Beach, Virginia, October 16, 1999

“Viagra – One Year Later”, Primary Care Conference, Sentara Virginia Beach General (sponsored by Pfizer), January 27, 2000

“Periurethral Prostatic Microwave Thermotherapy Using the Thermatrix TMX-2000: Follow up of a Randomized, Blinded Study Comparing TUMT with a Sham Procedure in Patients with BPH” , Southeastern Section AUA April 2, 2000

”Advances in BPH Treatment” – Boehringer Ingelheim, Virginia Beach, VA – May 20, 2000

“Periurethral Prostatic Microwave Thermotherapy Using the Thermatrix TMX-2000; Follow up of a Randomized, Blinded Study Comparing TUMT with a SHAM Procedure in Patients with BPH” – Oral Abstract, Northeastern Section of the AUA, Pittsburgh, Pennsylvania, September 14-17, 2000.

Talk “Urologic Infectious Diseases”, Primary Care Conference, Sentara Virginia Beach General, September 21, 2000

“Periurethral Prostatic Microwave Thermotherapy Using the Thermatrix TMX-2000; Follow up of a Randomized, Blinded Study Comparing TUMT with a SHAM Procedure in Patients with BPH” – Oral Abstract, Mid-Atlantic Section of the AUA, Rio Grande, Puerto Rico, October 15-18, 2000.

Talk “BPH: A Primary Care Perspective”, Sponsored by MERCK, Virginia Beach, Virginia, October 21, 2000

Talk “A Urologist’s Choice of Treatment for BPH” Merck, Virginia Beach, Virginia, January 18, 2001

Talk “Genitourinary Infections Hospital and Outpatient Settings” – Ortho-McNeil – Virginia Beach, Virginia, June 19, 2001

Talk “UTI’s and Prostatitis” – Ortho-McNeil – Virginia Beach, Virginia, July 13, 2001

Northeastern Section American Urological Association Annual Meeting, Boca Raton, FL, December 13-16, 2001, Presentation on BPH and Minimally Invasive Therapy

BPH Regional Speaker Meeting – Dallas, TX, January 18 – 19, 2002

“Recent Advances in Overactive Bladder”, Primary Care Conference, Sponsored by Sentara Virginia Beach General Hospital, Virginia Beach, VA, February 21, 2002

American Lithotripsy Society, Urology Society of America, Combined Annual Meetings, Hyatt Regency Lake Las Vegas Resort, Henderson, Nevada, March 14-17, 2002, Presentation on BPH and Update on Minimally Invasive Therapy

TherMatrix, Atlanta, GA ~ November 21-22, 2002

“Update on Benign Prostatic Hypertrophy” by Dr. Gregg Eure, Sentara Virginia Beach General Hospital, Grand Rounds, Virginia Beach, VA, December 17, 2002

URO Speaker Meeting, Los Cabos, Mexico ~ March 13-16, 2003 [Program Chair/Director]

Virginia Academy of Physician Assistants Summer CME Conference, Virginia Beach, Virginia, Summer 2003

“Management of Prostate Disorders for the Primary Care Physician – Eastern Virginia Medical School Norfolk, VA June 4, 2003

TherMatrix Peer to Peer Meeting Columbus, OH June 9, 2003

TherMatrix Peer to Peer Meeting Buffalo, NY June 10 – 11, 2003

“Update on Benign Prostatic Hypertrophy” Virginia Beach, VA June 17, 2003

BPH Disease Progressions: New Treatment Paradigms – GlaxoSmithKline – August 2003

Benign Prostatic Hyperplasia, Primary Care Conference, Sentara Virginia Beach General Hospital, Virginia Beach, VA, August 14, 2003

TherMatrix Peer to Peer Meeting Memphis, TN August 21 – 22, 2003

“Current Trends in the Management of Benign Prostatic Conditions”, Expert Faculty Speaker, DAW Communications, Norfolk, Virginia, September 30, 2003

Prostatitis and Genital Urinary Tract Infection, Primary Care Conference, Sentara Virginia Beach General Hospital, Virginia Beach, VA, September 11, 2003

“Prostate Cancer Update – 2003, Sentara Virginia Beach General Hospital, September 18, 2003

“BPH-A Concise Review of Therapies”, Sentara Bayside Hospital, Virginia Beach, VA, October 23, 2003

New York Section, American Urological Association, Greece, October 12-17, 2003
Talk: Transurethral Microwave Thermotherapy (TUMT) Using The Thermatrix TMx2000TM Durability Exhibited in a Study Comparing TUMT with a Sham Procedure in Patients With Benign Prostatic Hyperplasia (BPH)

“Management of BPH”, by Dr. Gregg Eure, Richmond Urologic Forum, Jefferson Hotel, Richmond, VA, February 21, 2004

URO 2004, Key Biscayne, FL ~ March 4-7, 2004

“New Advances in the Treatment of Erectile Dysfunction” by Dr. Gregg Eure, Primary Care Conference, Sentara Virginia Beach General Hospital, Virginia Beach, VA, March 11, 2004

“The Changing Landscape in the Treatment of Erectile Dysfunction”, by Dr. Gregg Eure, Lilly ICOS Lecture Series, Virginia Beach, Virginia, March 17, 2004

“Treatment Modalities of Erectile Dysfunction” by Dr. Gregg Eure, Portsmouth Academy of Medicine General Meeting, Portsmouth, Virginia, May 3, 2004

“Prostate Cancer: Hormone Therapy” by Dr. Gregg Eure, Cancer Conference, Sentara Virginia Beach General Hospital, Virginia Beach, Virginia, July 6, 2004

“Prostate Cancer Update-2004”, Sentara Virginia Beach General Hospital, September 9, 2004

Managing BPH: A Primary Care Challenge for the 21st Century, Cary, NC October 20, 2004

“Benign Hyperplasia: Men’s Health Challenge for the 21st Century”, Eastern Virginia Medical School, November 17, 2004

Annual Kimbrough Urological Seminar, Sheraton Waikiki Hotel, Honolulu, HI, January 16, 2005, Presentation TUMT and Sexual Function

ForTec Medical Systems, GreenLight PVP Workshop: BPH Management, Portsmouth Naval Medical Center, Portsmouth, VA, February 1, 2005

State of the Art Urology, 2005: BPH A Concise Review of Therapies, September 2005

“Bladder Matters: New Perspectives for Pelvic Management”, Ortho-Urology and Ditropan XL, Fairfax, VA, August 11, 2005

Men’s Health Seminar: Managing BPH & GreenLight PVP, Norfolk, VA, December 8, 2005

“Advanced Concept Summit on PVP”, Atlanta, GA ~ February 7, 2006 (LASERSCOPE)

Treatment of Enlarged Prostate “Laser PVP – The New Gold Standard” February, 16, 2006 SVBGH

“Advanced Concept Summit on PVP”, Washington, D.C. ~ June 7, 2006 (LASERSCOPE)

“Current Trends in the Treatment of BPH: Minimally Invasive Thermotherapy”, Boston, MA ~ June 24, 2006 (TherMatrix)

2006-2007 AUA Leadership Program, Linthicum, MD ~ July 28-30, 2006

“Minimally Invasive and Laser Therapies for BPH” State-of-the-Art Lecture, Northeastern Section of AUA Annual Meeting, Ottawa, Canada ~ September 7, 2006 (Boehringer-Ingelheim)

“Understanding the ED Treatment Paradigm”, Newport News, VA ~ September 20, 2006

“Prostate Cancer Update – 2006”, Sentara Virginia Beach General Hospital ~ September 28, 2006

“Understanding the ED Treatment Paradigm” (Cialis), Galax, VA ~ October 3, 2006

Corporate Presentation on Thermatrix and GreenLight (AMS), Minneapolis, MN ~ October 23, 2006

“Current Trends in the Treatment of BPH: Minimally Invasive Thermotherapy”, Baltimore, MD ~ November 4, 2006 (AMS)

AMS Course, Washington, D.C. ~ November 17, 2006

PVP/HPS Training, Virginia Beach, VA (AMS) ~ November 29, 2006

PVP/HPS Training, Newport News, VA (AMS) ~ December 12, 2006

“Current Trends in the Treatment of BPH: Minimally Invasive Thermotherapy”, Costa Mesa, CA ~ January 26-27, 2007 (AMS)

“Current Trends in Treatment of BPH: Minimally Invasive Thermotherapy”, Phoenix, AZ ~ March 9-10, 2007 (AMS)

TherMatrix TMX3000 Meeting, Chicago, IL (AMS) ~ March 23-24, 2007

PVP/HPS Training, San Francisco, CA (AMS) ~ April, 18, 2007

HPS/TherMatrix Peer to Peer Presentation (AMS) Washington, DC ~ May 2-3, 2007

HPS Peer to Peer Presentation (AMS) Albany, NY ~ May 31, 2007

PVP/HPS Training, Albany, NY (AMS) ~ June 1, 2007

“Identifying and Managing Men with Enlarge Prostate (EP): Targeting Symptoms at Their Source”, Virginia Beach, VA (GSK) ~ August 1, 2007

FLOMAX Educational Speaker Presentation, Virginia Beach, VA (BI) ~ August 16, 2007

Avodart Advisory Board, Washington, DC (GSK) ~ August 24, 2007

“Identifying and Managing Men with Enlarge Prostate (EP): Targeting Symptoms at Their Source”,

Virginia Beach, VA (GSK) ~ August 31, 2007

FLOMAX Educational Speaker Presentation, Virginia Beach, VA (BI) ~ September 6, 2007

PVP/HPS Training, Lebanon, NH (AMS) ~ September 13, 2007

“Identifying and Managing Men with Enlarge Prostate (EP): Targeting Symptoms at Their Source”, Virginia Beach, VA (GSK) ~ September 17, 2007

TMX 3000 Peer to Peer Presentation, Richmond, VA (AMS) ~ September 19, 2007

TherMatrix Training, San Francisco, CA (AMS) ~ October 12-13, 2007

“BPH Expert Panelist” Minimally Invasive Therapy for BPH, Miami, FL (AMS) ~ January 9, 2008

PVP/HPS Training, London, Ontario, Canada (AMS) ~ January 23-25, 2008

PVP/HPS Training, London, Ontario, Canada (AMS) ~ February 20-21, 2008

“Cialis Dosing Options: Which one is right for your patients?”, Lebanon, VA (Lilly) ~ April 9-10, 2008

“Cialis Dosing Options: Which one is right for your patients?”, Blacksburg, VA (Lilly) ~ April 28, 2008

GreenLight HPS Advanced Concepts Workshop, Chicago, IL (AMS) ~ May 2-3, 2008

“Vaporize Your Patient’s BPH Concerns With The GreenLight Laser”, Virginia Beach, VA ~ June 10, 2008

Family Medicine Review Course “BPH & Prostate Screening” Virginia Beach, VA (EVMS) ~ June 18, 2008

MIS Conference, Williamsburg, VA ~ August 15-17, 2008

PVP/HPS Training, Toronto, Ontario, Canada (AMS) ~ August 20-21, 2008

Grand Rounds at University of Maryland , Washington, DC (AMS) ~ September 17-18, 2008

Grand Rounds at University of Miami, Miami, FL (AMS) ~ October 1-3, 2008

MEDICAL MEETINGS

Benign Prostatic Hypertrophy Speakers Conference, Hilton Head Island, South Carolina, August 30-31, 1991

Prostate Cancer and Urothelial Cancer, Stouffer Hotel, Orlando, Florida, October 3-5, 1991

Treatment of Prostate Cancer, Norfolk, Virginia, December 7, 1991

New Approaches in the Treatment of Prostate Cancer and Benign Prostatic Hypertrophy, December 7, 1991

Annual Residency Workshop, Lewis Hall, Auditorium, EVMS, Norfolk, Virginia, April 25, 1992

Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 18-20, 1992

Ultrasound Conference, Norfolk, Virginia, June 27-28, 1992

Mid-Atlantic Section, American Urological Association, Williamsburg, Virginia, September 20-23, 1992

Intravesical Alpha 2b-Interferon, Newark, New Jersey, October 9, 1992

Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 17-20, 1993

AUA Research Conference on Immunology and Inflammation, Houston, Texas, August 20-23, 1993

Mid-Atlantic Section, American Urological Association, West Palm Beach, Florida, September 18-22, 1993

Nocturnal Enuresis: New Perspectives for the 90's, Rancho Mirage, California, October 1-3, 1993

Annenberg Educational Symposium-PNE: New Perspectives for the Nineties, November 5, 1993

East Coast Symposium on Endoscopic Surgery, SLH, Norfolk, Virginia, November 6, 1993

AUA Conference on Prostate Cancer, Washington D.C., December 3-5, 1993

4th International Conference on BPH/Prostate and Urothelial Cancer, Orlando, Florida, March 10-12, 1994

New Advances in BPH and Prostate Cancer, Urology Update for Primary Care Physicians, Virginia Beach, Virginia, October 8, 1994

Mid-Atlantic Section, American Urological Association, San Francisco, California, May 16-19, 1994

Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 16-19, 1994

Urotrend 2000, Washington, D.C., July 16, 1994

Southwest Oncology Group PIVOT Study Meeting, Minneapolis, Minnesota, August 16-18, 1994

Liarozole Investigators Meeting, Chicago, Illinois, September 30- October 1, 1994

Program Director, "New Advances in BPH and Prostate Cancer" Conference, October 8, 1994

New Developments in Prostate Cancer Management, Pebble Beach, California, January 11-13 1995

Virginia Urological Society Meeting Williamsburg, Virginia, May 5-7, 1995

Visiting Faculty in Interferon' Meeting, Rancho Mirage, California, June 2-3, 1995

A Commitment to Urology: Therapeutic Innovations in BPH and Prostate Cancer, Williamsburg, Virginia, June 8-10, 1995

Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 22-25, 1995

Mid-Atlantic Section, American Urological Association, Southampton, Bermuda, September 17-20, 1995

American Society for Reproductive Medicine, Seattle, Washington, October 6-12, 1995

SWOG/Society of University Urologists Meeting, New Orleans, Louisiana, October 25-28, 1995

PLESS Investigator's Meeting, San Diego, California, November 25-29, 1995

Partners in Urologic Surgery, Chicago, Illinois, August 10-11, 1996

Mid-Atlantic, Washington, D.D., October 27-30, 1996

Zeneca Speaker Support Prostate Cancer Update meeting, Litchfield Park, Arizona, January 16-19, 1997

Mid-Atlantic Section, American Urological Association, New Orleans, LA April 12-17, 1997

Investigators Meeting Merck PLESS Program, San Diego, CA, May 31-June 2, 1997

Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 19-22, 1997

Hoechst Marion Roussell, Inc. Nilandron FLARE Protocol meeting, Naples, Florida, October 5-7, 1997

Viagra Speakers Bureau Meeting, Lake Buena Vista, Florida, February 20-22, 1998

Schering Oncology Meeting, Montreal, Quebec, February 27 - March 1, 1998

Mid-Atlantic Section, American Urological Association, San Diego, CA May 29-June 4, 1998

Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 19-21, 1998

THERMATRX Investigator's meeting, New York, New York, September 3-4, 1998

Prostate Cancer: New Strategies for Diagnosis, Staging and Management, Chicago, IL, July 10-12, 1998

Mid-Atlantic Section, American Urological Association, Palm Beach, FL October 3-7, 1998

SWOG, Annual Meeting, San Antonio Texas, October 20-24, 1998

Prostate Cancer: New Strategies for Diagnosis, Staging and Management, Medical Education Collaborative, Miami, FL November 6, 1998

Levaquin Urology Speaker's Training Program, Arizona Biltmore Resort & Spa, Phoenix, Arizona, January 14-17, 1999

THERMATRX Investigator's meeting, Chicago, IL February 26, 1999

Southeast Section, AUA, Charleston, SC, March 19-23, 1999

New Frontiers in the Diagnosis and Treatment of Prostate Diseases, Medical Education Collaborative, Washington, DC April 9, 1999

National Urology Consultants' Meeting, Merck & Co., Orlando, FL, April 16-18, 1999

American Urological Association Annual Meeting, Dallas, TX May 1-6, 1999

AUA: Advances in BPH Research Conference (by invitation only), Houston, TX, July 30-August 1, 1999

Mid-Atlantic Section, American Urological Association, Hilton Head, SC October 3-6, 1999

AUA Urolithiasis Update, Washington, DC, December 10 – 12, 1999

National Urology Consultants Meeting, Merck & Co., Phoenix, AZ, February 25-27, 2000

URO2000, Speaker's Meeting Boehringer Ingelheim, Cancun Mexico, March 16-19, 2000

American Urological Association Annual Meeting, Atlanta, GA, April 29-May 4, 2000

Zeneca Advisory Board Meeting, "Current Practice Trends in the Treatment of Prostate Cancer", Ponte Verda, Florida, June 8 – 11, 2000

Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 22-25, 2000

THERMATRX Investigator's meeting, Providence, R.I., July 28 – 30, 2000

"Radiology: Today and Tomorrow" by Dr. John O'Neil, Grand Rounds, Sentara Virginia Beach General Hospital, Virginia Beach, VA, February 27, 2001

THERMATRX Investigator's meeting, Park City, Utah, February 8-11, 2001

"Prostate Cancer", Grand Rounds, Sentara Virginia Beach General Hospital, Virginia Beach, VA, March 6, 2001

URO2001, Speaker's Meeting Boehringer Ingelheim, Santa Barbara, California, April 26-29, 2001

Erectile Dysfunction Preceptorship, Boston, MA Program May 3 – 4, 2001

American Urological Association Annual Meeting, Anaheim, California, June 2-7, 2001

"Adjuvant and Neoadjuvant Hormonal Therapies", Norfolk, VA, June 13, 2001

Seaboard Urological Association-Annual Meeting, Nags Head, North Carolina, June 21-24, 2001

RiskAware for Physicians, Independent Study Course, Medical Risk Management, Inc., July 10, 2001

Cancer Conference, Sentara Virginia Beach General Hospital, Virginia Beach, VA, November 6, 2001

Flomax Advisory Board Meeting, Four Seasons Hotel, Philadelphia, PA, October 26 –28, 2001

Northeastern Section American Urological Association Annual Meeting, Boca Raton, FL, December 13-16, 2001.

TherMatrix/American Medical Systems SAB Meeting Scottsdale, AZ January 10 – 13 2002

American Lithotripsy Society, Urology Society of America, Combined Annual Meetings, Hyatt Regency Lake Las Vegas Resort, Henderson, Nevada, March 14-17, 2002.

URO2002, Speaker's Meeting Boehringer Ingelheim, Los Cabos, Mexico, March, 2002, Program Chairman

"Power Point For Physicians", Eastern Virginia Medical School, Norfolk, VA, April 27, 2002

American Urological Association Annual Meeting, Orlando, FL, May 24-30, 2002

"Recent Advances in the Management of Prostate Cancer", Washington, DC, August 16, 2002

Mid-Atlantic American Urological Association Annual Meeting, Baltimore, Maryland, October 9, 2002

"New Techniques in Endourology: Laser, PCNL and Ureteroscopy", Crowne Plaza, New York, NY, December 7, 2002

Flomax Advisory Board Meeting 2003 Key Biscayne, FL January 10 – 11, 2003

TherMatrix Peer to Peer Meeting, Philadelphia, PA, January 22, 2003

TherMatrix Peer to Peer Meeting, Washington, DC, January 23, 2003

Urology Oncology Meeting, Tucson, AZ ~ February 16-19, 2003

GlaxoSmithKline and Avodart National Speaker Training Meeting, Denver, CO, March 7 – 9, 2003

American Urological Association Annual Meeting, Chicago, IL, April 26-May 1, 2003

TherMatrix Peer to Peer Meeting Philadelphia, PA, May 19, 2003

TherMatrix Peer to Peer Meeting Portland, OR, June 24, 2003

TherMatrix Peer to Peer Meeting San Francisco, CA June 25-26, 2003

TherMatrix Peer to Peer Meeting Pittsburg, PA, July 16, 2003

TherMatrix Peer to Peer Meeting, Orlando, FL July 17 – 18, 2003

GlaxoSmithKline Reduce Investigators Meeting, Hyatt Regency McCormick Place, Chicago, IL July 23 –24, 2003

BPH & Beyond Key Opinion Leader, Scientific Session, Waldorf-Astoria, New York, NY, October 28-29, 2003

Flomax Advisory Board Meeting, The Ritz Carlton Cancun, Mexico January 16 – 17, 2004

SBCD Start Up Meeting, Hyatt Regency Hill Country, San Antonio, TX, February 22-24, 2004

TherMatrix Peer to Peer Meeting, Atlanta, GA, April 15, 2004

GreenLight PVP Training Course, Salem, VA, April 23, 2004

GreenLight PVP Training Course, Fredericksburg, VA, May 18, 2004

“TherMatrix Dose Optimized ThermoTherapy, A Different Kind of TUMT” by Dr. Gregg Eure, 3rd IAUAA Scientific & Educational Program, Hilton, San Francisco, California, May 9, 2004

American Urological Association Annual Meeting, San Francisco, CA, May 8-13, 2004

TherMatrix/American Medical Systems Dose Optimized ThermoTherapy Training, Presenter 7-12- “Data Review” and “A Physician’s Perspective”, Minneapolis, MN, July 11-12, 2004

The New York Academy of Medicine Conference, New York, NY September 29, 2004

Lilly ICOS Investigators Meeting, Phoenix, AZ October 1-2, 2004

GreenLight PVP Training Seminar, Reston, VA, February 8, 2005

Sanctura UroBureau Faculty Meeting, Scottsdale, AZ, February 18 – 19, 2005

QLT Investigator Meeting, New Orleans, LA ~ April 8-10, 2005

TherMatrix Peer to Peer Meeting Baltimore, MD May 20, 2005

TherMatrix Peer to Peer Meeting, New York, NY June 9, 2005

Boehringer Ingelheim Flomax Advisory Board Meeting New York, NY, June 11, 2005

ForTec Medical Systems, GreenLight PVP Workshop: BPH Management, Washington, DC, June 28, 2005

TherMatrix Peer to Peer Meeting, New York, NY, August 25, 2005

Prostate Screenings, Sentara Virginia Beach General Hospital, September 21, 2005

GlaxoSmithKline Avodart Advisory Board Meeting, Sheraton Hotel, Philadelphia, PA, December 2, 2005

GlaxoSmithKline Avodart Speaker Training Program Las Vegas, NV March 3 – 4, 2006

National Advisory Board, New York City, NY ~ May 5-6, 2006 (Boehringer-Ingelheim)

AUA Annual Meeting, Atlanta, GA ~ May 19-24, 2006

GSK Investigator Meeting, Chicago, IL ~ June 15-16, 2006

Multidisciplinary Approach to Prostate Cancer in 2006, Dr. Leonard Gomella ~ June 19, 2006

“LVHG Start up Meeting”, Cialis Trial, Dallas, TX ~ August 10-12, 2006 (Lilly)

“Pediatric Urology and Male Infertility”, Dr. Stuart Howards ~ September 26, 2006

“Intersex”, Dr. Stuart Howards ~ September 26, 2006

“Maintenance of Certification”, Dr. Stuart Howards ~ September 27, 2006

Mid-Atlantic AUA, Washington, D.C. ~ October 12-14, 2006

Flomax National Advisory Board, Miami, FL ~ December 8-9, 2006

Spectrum Investigator Meeting, Fort Worth, TX ~ January 12-13, 2007

“Hereditary Colon Cancer Syndromes”, Dr. Davis Stockwell III ~ March 20, 2007

Joint Advocacy, Washington, DC ~ March 24-27, 2007

Spectrum Investigator Meeting, Phoenix, AZ ~ March 30-April 1, 2007

“Pediatric Dermatology Potpourri”, Heather Miller, PAC ~ April 17, 2007

Minirin Investigator Meeting, Bonita Spring’s, FL ~ May 4-5, 2007

AUA Annual Meeting, Anaheim, CA ~ May 19-24, 2007

“Preoperative Testing: Essential or Excessive”, Dr. Steven Johnson ~ June 19, 2007

Boehringer Ingelheim Advisory Board Meeting, Washington, DC ~ June 21, 2007

Organon National Advisory Board Meeting, Washington, DC ~ June 22-23, 2007

“Basics of Oncologic PET Imaging”, Dr. Jonathon White, MD. PhD ~ July 3, 2007

“Pediatric Sports Injuries”, Dr. Sandra Glasson ~ July 31, 2007

“Skin Cancer”, Dr. Kristen Martin ~ August 7, 2007

National Key Opinion Leader Advisory Board for Avodart, Washington, DC ~ August 24-25, 2007

“Minimally Invasive Spine Surgery”, Dr. Joseph Ong ~ September 11, 2007

“The Biology of Nodal Metastases in Renal Cell Carcinoma”, Dr. Christopher Woods ~ September 24-25, 2007

“Prostate Cancer: Review and Update”, Dr. Raymond Lance ~ October 2, 2007

“Prostate Biopsy: How Many Cores and What to do with the Information”, Dr. Stephen Freedland ~ January 29, 2008

Cialis Speaker Training, Scottsdale, AZ ~ February 29, 2008

Joint Advocacy, Washington, DC ~ March 28-April 1, 2008

AUA Annual Meeting, Orlando, FL ~ May 16-22, 2008

Mid-Atlantic AUA, Cambridge, MD ~ August 24-28, 2008

ACADEMIC COURSES

Ultrasound Workshop, Dallas, Texas, January 10-11, 1992

Candela Lasertripsy Workshop, Portsmouth, Virginia, January 21, 1993

Genitourinary Pathology, February 19-24, 1993

Laparoscopic Urology 1993, April 22-23, 1993

Pathology and Uro-Radiation, Dearborn, MI, February 5-10, 1994

Uro-pathology, Washington, D.C., January 23-27, 1995

Pathology/Uroradiology, February 11-16, 1995

Transperineal Radioactive Seed Implantation Course, Endo-Surgery Institute, Cincinnati, Ohio, March 13-14, 2000

Viadur Advisory Board and Workshop, Washington, DC, November 11, 2000

Faculty Training Program, “Hormonal Therapy in Prostate Cancer: Advancing the Continuum of Androgen Suppression”, Boca Raton, Florida, March 9-11, 2001

Bayer’s Scientific Affairs Erectile Dysfunction Preceptorship, Boston, MA, May 3-4, 2001

Speaker’s Training for Avodart, Las Vegas, NV ~ March 3-4, 2006

RESEARCH/RESEARCH ACTIVITIES

Research Chairman, Urology of Virginia Research Department

PRINCIPAL INVESTIGATOR-BPH

Lilly-ICOS – H6D-MC-LVHK – A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia – **Open Trial**

AMSPE0603-Greenlight - A Prospective Clinical Study for GreenLight HPS™ in Treatment of Obstructive Benign Prostatic Hyperplasia – Closed Trial

AMS055 – Thermatrix Evaluation of the Safety and Tolerability of TherMatrix TMx-2000™ BPH Thermotherapy System for the Treatment of Benign Prostatic. – Closed Trial

GSK DOP – UVA001 – A randomized, Placebo-controlled, Double-Blind Study of the Use of Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate. – **Open Trial**

QLT, LTD – BPH Plus – QLT0074 BPH 003: A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy with Lemuteporfin in Patients with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia – Closed Trial

Lilly-ICOS – H6D-MC-LVHG – A Randomized, Double-blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-day Dosing for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia. - Closed Trial

Lilly-ICOS – H6D-MC-LVHG (Open-Label Extension Phase)– A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia – **Open Trial**

SPECTRUM (Protocol SPI-153-06-1) – A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hypertrophy (BPH) – Closed Trial

Evaluation of Transurethral Microwave Therapy in the treatment of benign prostatic hypertrophy (BPH), THERMATRX, INC – September 1998 - Closed Trial

A Randomized Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5 mg in the Treatment of and Prevention of Progression of Benign Prostatic Hypertrophy, GLAXO WELLCOME, INC – October 1997 - Closed Trial

CO-INVESTIGATOR-BPH

PFIZER – Detrol/Flomax _ A Randomized, Double-Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER plus Tamsulosin) Study to Evaluate the Clinical Efficacy and Safety of Tolterodine ER 4mg in Men who have frequency and urgency, with or without Urinary urge Incontinence, with or without bladder outlet obstruction. – Closed Trial

A Post-Market Data Collection Clinical Study Evaluating the Uroflow and Symptoms Alleviation of Water Induced Thermotherapy with the Thermoflex System, ARGOMED, December 1, 1999- Closed Trial

Prostate Cancer Prevention Trial. To evaluate the administration of Proscar for the prevention of prostate cancer, NATIONAL CANCER INSTITUTE/SWOG – Closed Trial (1993)

Two year, open extension to double-blind randomized placebo controlled multi-center study to investigate the long-term effects of Finasteride in patients with BPH, Protocol #048-04-10/study MK906, MERCK RESEARCH LABORATORIES – Closed Trial

PRINCIPAL INVESTIGATOR – Prostate Cancer

GSK AVO108943 – A Randomized, Double-Blind, Parallel Group Study Comparing Casodex 50mg plus Placebo to Casodex 50mg plus Dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by

Rising PSA) Followed by Two-Year Extension Phase – **Open Trial**

GSK-REDUCE (Site 2): A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg. Administered Orally Once Daily for Four Years to Reduce the Risks of Biopsy –Detectable Prostate Cancer, Protocol G1198745/ARI40006-**Open Trial**

REDEEM – GlaxoSmithKline – A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management AVO105948 - **Open Trial**

Protocol No. GTx-006-211: A Multicenter, Phase IIb, Four Arm, Dose Finding, Randomized, Placebo-Controlle Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20 mg, 40 mg, & 60 mg. Daily of GTx-006 in Men with High Grade Prostate Intraepithelial Neoplasia (PIN), Closed Trial

CO-INVESTIGATOR-Prostate Cancer

S000-Selenium and Vitamin E Cancer Prevention (SELECT), SWOG, **Open Trial**

Sanofi-Adventis: XRP6976J/3501 – A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD® - leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy. – **Open Trial**

CASODEX – AstraZeneca – A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex) verses Placebo in Patients with Early Prostate Cancer. – **Open Trial**

COMPARE – Sanofi Synthelabo – Prospective, Observational Registry of The Management of Men with Prostate Cancer and a Rising PSA Following Definitive Surgical or Radiological Treatment of the Primary Tumor: PCA Registry COMPARE (Comprehensive, Observational, Multicenter Prostate Adenocarcinoma Registry). – Closed Trial

GTX 300203 – A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremfene Citrate for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy. - Closed Trial

GTX High Grade PIN – A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremfene Citrate for the Prevention of Prostate Cancer in Men with High Grade Intraepithelial Neoplasia (PIN) – Protocol No. G300104 - **Open Trial**

PCPT Long Term – S0437 – Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed with Prostate Cancer. – **Open Trial**

D9901: A Randomized, Double-Blind, Placebo Controlled Trial of Immunotherapy with Autologous Antigen-Loaded Dendritic Cells (Provenge, APC8015) For Asymptomatic Metastatic Hormone-Refractory Prostate Cancer Prostate Cancer, Dendreon Corporation, **Open Trial**

“A Randomized, Double-Blind, Placebo-Controlled Trial of Immunotherapy with Autologus Antigen-Loaded Dendritic Cells (Provenge, APC8015) for Asymptomatic Metastatic Hormone-Refractory Prostate Cancer”, Protocol D9902, Dendreon Corporation, **Open Trial**

DENDREON9902B - “A Randomized, Double-Blind, Placebo Controlled Phase 3 Trial of Immunotherapy with Autologus Antigen Presenting Cells Loaded with PA2024 (Provenge, APC8015) in Asymptomatic Subjects with Gleason Sum ≤ 7 , Metastatic, Androgen Independent Prostatic Adenocarcinoma”, ProtocolD9902B, Closed Trial

DENDREONPB01 - An Open Label, Single Arm Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (APC8015F) for Subjects with Objective Disease Progression and Disease-Related Pain on Trial D9902 Part B, Protocol PB01, Closed Trial

D9903: A Phase II, Open Label, Single Arm Trial with Cryopreserved Autologous Antigen-Loaded Dendritic Cells (APC8015F) for Hormone-Refractory Prostate Cancer Patients with Objective Disease Progression, Dendreon Corporation, Closed Trial

Autologous PAP-loaded Dendritic Cell Vaccine (APC8015, Provenge) in Patients with Non-Metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: A Randomized, Controlled Double-Blind Trial. Protocol #Dendreon P-11, Dendreon Corporation, Closed Trial

SWOG9917-L-Selenium Based Chemoprevention of Prostate Cancer Among Men with High Grade Prostatic Intraepithelial Neoplasia, Closed Trial

JPR-3 “Phase III Randomized Trial Comparing Total Androgen Blockade Plus Pelvic Irradiation in Clinical Adenocarcinoma of the Prostate, SWOG, Closed Trial

SWOG-JPR-7 – A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients with Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer. – Closed Trial

SWOG9921 – Adjuvant Androgen Deprivation versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III”, Closed Trial

“SWOG 0032, Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate.”, SWOG, Closed Trial

IDOO-156: A Randomized Phase III Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer, SWOG, Closed Trial

RTOG P-0014 – A Phase III Randomized Study of Patients with High-Risk, Hormone-Naïve Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy, SWOG, **Open Trial**

SWOG9346 – Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III, **Open Trial**

Prostate Cancer Intervention Versus Observation Trial (PIVOT): A randomized trial comparing radical prostatectomy versus palliative expectant management for the treatment of clinically localized prostate cancer, SWOG, September 1995 – Closed Trial

Repeat doses of Strontium – 89 adjuvant to maximum androgen blockade in newly diagnosed stage D2 prostate cancer patients with bone metastases: A Phase II trial, MEDIPHYSICS, INC. (Amersham Healthcare) December 1997 Closed Trial

A phase II double-blind comparison of safety and efficacy of ABT-627 versus placebo in subjects with symptomatic hormone refractory prostate cancer (An oral pain medication for patients who require Opioid Analgesia) (M96-500), ABBOTT LABORATORIES January 1998 – Closed Trial

Dose ranging study comparing best medical therapy with and without ABT-627 for the treatment of men with asymptomatic hormone refractory adenocarcinoma of the prostate (M96-594), ABBOTT LABORATORIES May 1998 – Closed Trial

An extension study to evaluate the safety and tolerability of ABT-627 in subjects with hormone refractory adenocarcinoma of the prostate (M97-739) ABBOTT LABORATORIES May 1998 – Closed Trial

A randomized double blind study comparative trial of Bicalutamide (Casodex) 150 mg versus placebo each in combination with castration as second line therapy for patients with asymptomatic metastatic prostate cancer. ZENECA PHARMACEUTICALS September 1998 – Closed Trial

Phase III randomized study of Abareliz-Depot versus Lupron with or without Casodex, PRAECIS PHARMACEUTICALS, INC. December 1998 – Closed Trial

SWOG 9346 A Phase III trial of Intermittent Androgen Deprivation in patients with Stage D2 prostate cancer, SWOG October 1995 – Closed Trial

SWOG JPR.3 intergroup phase III randomized trial comparing total androgen blockade versus CO-total androgen blockade versus total androgen blockade plus pelvic irradiation in clinical stage T3-4, N0, M0 adenocarcinoma of the prostate, SWOG November 1996 – Closed Trial

SWOG 9205 Central prostate cancer serum repository protocol, May 1998 – Closed Trial

A randomized comparative trial of Casodex versus Flutamide used in combination with medical castration in patients with untreated metastatic prostate cancer. Comparison of complete androgen blockade with one of two LHRH agonists and one of two anti-androgens to determine difference in toxicity and equivalence of efficacy between the respective combinations for men with metastatic prostate cancer, ZENECA PHARMACEUTICALS – Closed Trial (1992)

A randomized double-blind controlled Phase III trial evaluating Zoledronate plus standard therapy versus placebo plus standard therapy in patients with recurrent carcinoma of the prostate who are asymptomatic with castrate levels of testosterone and have rising PSA levels without radiologically evident metastatic disease, Novartis Pharmaceuticals-Closed Trial (1999)

A multi-center open labeled trial to evaluate the safety and efficacy of Goserelin Acetate 10.8 mg (Zoladex, ZD 9393) in subjects with advanced carcinoma of the prostate, ZENECA PHARMACEUTICALS – Closed Trial (1995)

A randomized double blind comparative trial of Bicalutamide (Casodex) versus placebo in patients with early prostate cancer, (705411/0023) ZENECA PHARMAECUTICALS – Closed Trial (1995)

Phase II evaluation of oral ALRT1057 in patients with advanced prostate cancer, LIGAND – Closed Trial

An international phase II randomized double blind multi-center study to determine the safety and efficacy of three different doses of Liarozole in patients with rising prostate specific antigen levels after definitive treatment – LIA-INT –26, JANSSEN RESEARCH FOUNDATION – Closed Trial

A phase III open randomized multi-center trial to determine the efficacy and safety of the combination of Liarozole with Prednisone in patients with relapsed hormone resistant prostate cancer (LIA-INT-29), JANSSEN – Closed Trial

CO-INVESTIGATOR-Hot Flashes

A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Clinical Trial to Study the Efficacy and Safety of CyPat[®] (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in these Patients" Protocol PCA-301, Closed Trial

An Open Label Extension of the Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of Cypat[™] (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer patients and Its Impact on the Quality of Life in the these Patients. PCA-301A, Closed Trial

CO-INVESTIGATOR QUALITY OF LIFE

Quality Of Life Assessment In Patients Before An After Treatment For Carcinoma Of The Prostate, Devine-Tidewater Urology/Eastern Virginia Medical School, **Open Trial**

CO-INVESTIGATOR-Bladder Cancer

Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer, G. D. Searle NQ4-99-02-006, Closed Trial

SPECTRUM (Protocol SPI-611) – A Multicenter, Randomized Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical Eoquinâ as a Surgical Adjuvant Instilled in the Early Postoperative Period iin Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer – Closed Trial

Bioniche-HIS-0611-09692 – A Phase III, open-label, multicenter study of the efficacy and safety of MCC in the treatment of patients with non-muscle invasive (superficial) bladder cancer at high risk of progression and who are refractory to BCG. - **Open Trial**

SWOG4B-95-1, "MVAC in Organ Confined Bladder Cancer Based on p53 Status.", Closed Trial

"A National Phase II Trial of Intron, Interferon-Alfa 2b Plus BCG for treatment of Superficial Bladder Cancer", Closed Trial

A Multicenter Trial of Induction and 6 Courses of 3 Week Maintenance with BCG versus BCG plus Interferon Alpha-2b (Intron A) in Superficial Bladder Cancer, Closed Trial

Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer, Joint Effort of NCI, University of Wisconsin Comprehensive Cancer Center, and ILEX Oncology, Inc., November 1998-Closed Trial

A Prospective, Longitudinal Study of PathVysion™ Bladder Test in Patients with Transitional Cell Carcinoma of the Bladder, Closed Trial

Phase III randomized study of a single adjunctive instillation of intravesical AD32 (N Trifluoroacetyladiamycin – 14 – valerate) versus no adjunctive therapy immediately following transurethral resection in patients with multiple superficial (Ta/T1) bladder tumors, ANTHRA PHARMACEUTICALS February 1997 – Closed Trial

BTA Trak and BTA Stat Assays in serial samples from subjects with newly diagnosed or a history of bladder cancer, Protocol 9706-A, BARD DIAGNOSTICS March 1998 – Closed Trial

A randomized multi-center phase III clinical trial comparing BCI-immune activator with Adriamycin for the treatment of refractory carcinoma in situ with or without cystoscopically unresectable superficial bladder cancer (KLH study), November 1998 INTRACEL – Closed Trial

Comparative Phase II trial of intravesical Mitoxantrone (Novantrone versus no chemotherapy in Ta G1 or G2 superficial bladder cancer (Dr. Sarosdy), IMMUNEX CORPORATION, November 1998 – Closed Trial

SWOG 9460 Phase IIb randomized chemoprevention trial of N – (4HPR) Retinamide (4HPR) in transitional cell bladder carcinoma, SWOG, September 1997 – Closed Trial

SWOG 9455 Phase II study of 5FU infusion and alpha Interferon for treatment of advanced or recurrent metastatic adenocarcinoma of the bladder, SWOG, November 1996 – Closed Trial

CO-INVESTIGATOR-Erectile Dysfunction

"A Randomized, Double-Blind, Parallel, Placebo Controlled Study in Men with Erectile Dysfunction to Evaluate the Efficacy and Safety of Tadalafil When Sexual Attempts Occur at Specific Time Points After Dosing." Lily ICOS - Closed Trial

"An Open-Label, Multi-Center Single-Arm Study to Investigate the Safety, Tolerability and Efficacy of Flexible Doses of Vardenafil Given on Demand in African American, Hispanic and Caucasian Males with Erectile Dysfunction. Bayer Corporation Protocol No. 10786." Bayer-Closed Trial

A phase III long term open label flexible dose safety extension study of Apomorphine SL tablets in the treatment of male erectile dysfunction (M97-682) – Closed Trial

Evaluation of the safety and efficacy of transurethral Alprostadil/Prazosin HC1 for the treatment of erectile dysfunction (AP-02) VIVUS – Closed Trial

Long term evaluation of the safety and efficacy of transurethral Alprostadil/Prazosin in HC1 for the treatment of erectile dysfunction (AP-04) VIVUS – Closed Trial

A phase III efficacy and safety study comparing escalating doses of Apomorphine or placebo in the treatment of male erectile dysfunction (M97-763), TAP PHARMACEUTICAL – Closed Trial

A Phase III Efficacy and Safety Study of Three Fixed Doses of Apomorphine SL Tablets 2, 4, and 5 mg versus placebo in the treatment of male erectile dysfunction (M98-941), TAP PHARMACEUTICAL, December 1998-Closed Trial

A Phase III Two-Year, Long Term, Open-Label, Flexible Dose, Safety Extension Study of Apomorphine SL Tablets in the treatment of male erectile dysfunction (M98-936), TAP PHARMACEUTICAL, December 1998-Closed Trial

CO-INVESTIGATOR-INTERSTITIAL CYSTITIS

MediciNova, Inc: Protocol No. MN-001-CL-002 – Phase II: A Phase II, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to evaluate the Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients with Interstitial Cystitis. – Closed Trial

PRINCIPAL INVESTIGATOR-NOCTURIA

Ferring – FE992026 CS29 – A Randomized, Double-Blind, Placebo Controlled, Parallel group, Multi-Center Study with a Double Blind Extension Investigating the Efficacy and Safety of a Fast Dissolving (“Melt”) Formulation of Desmopressin for the treatment of Nocturia in Adults – **Open Trial**

PRINCIPAL INVESTIGATOR-INCONTINENCE/OVERACTIVE BLADDER

Study of Duloxetine HCl in Women of Different Demographic Characteristics and Comorbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety. Protocol F1J-US-SBCD, Eli Lilly, Closed Trial

CO-INVESTIGATOR-INCONTINENCE/OVERACTIVE BLADDER

Astellas VICTOR 905-UC-008 – A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESicare® (Solifenacin Succinate) or Placebo in Combination with Tamsulosin HCL for the Treatment of Residual OAB

Symptoms of Urgency and Frequency in Men. VICTOR: VESIcare® In Combination with Tamsulosin in QAB Residual Symptoms. – Closed Trial

Pfizer-AMBER A6061023-1150 – A Phase 2, 8-week, Multicenter, Randomized Double-Blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Tolerability and Safety of [S,S]-Reboxetine (PNU-165442G) for Stress Urinary Incontinence in Women. – Closed Trial

Pfizer-Detrol/Flomax – A Randomized, Double-Blind, Placebo-Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER plus Tamsulosin) Study to Evaluate the Clinical Efficacy and Safety of Tolterodine ER 4mg in Men who have Frequency and urgency, with or without Urinary urge incontinence, with or without bladder outlet obstruction. – Closed Trial

PROTOCOL: F1J-MC-SBBO(a), INVESTIGATOR: PETER O. KWONG, M.D.
DRUG: DULOXETINE HCL, Closed Trial

A Patient Acceptability Study of a Once Daily Formulation of Tolterodine. A Phase IIB, Open-Label, Single Arm Trial in Adults with Overactive Bladder and Symptoms of Urinary Frequency, Urgency, and/or Urge Incontinence, Closed Trial

A Phase 2, 8-Week, Multi-Center, Randomized Double-Blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Tolerability and Safety of [S,S]- Reboxetine (PNU-165442G) for Stress Urinary Incontinence in Women. Closed Trial

A Phase II, 8-Week. Multi-Center, Randomized Double-Blind, Placebo Controlled, Parallel Group Study Evaluating The Efficacy, Tolerability And Safety of (PNU-165442G) For Stress Urinary Incontinence In Women. Closed Trial

CO-INVESTIGATOR-ANTIBIOTIC EFFECT TO SPERMATOGENESIS

Medicis Pharmaceutical Corp.- A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Minocycline Extended-Release Tablets on Spermatogenesis in Human Males – Closed Trial

CO-INVESTIGATOR-POST-VASECTOMY SEMEN SAMPLES

CONTRAVAC, INC – Study (Protocol #1) – Comparison of Hemacytometer Counts with SpermCheck® Vasectomy Results of Post-Vasectomy Semen Samples. – Closed Trial

CO-INVESTIGATOR-RENAL CELL CARCINOMA

E2085 – A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib verses Sorafenib verses Placebo in Patients with Resected Renal Cell Carcinoma – **Open Trial**

ECOG 2805 – A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib verses Sorafenib verses Placebo in Patients with Resected Renal Cell Carcinoma – **Open Trial**

BIBLIOGRAPHY

Eure, Gregg R., Ladaga, Leopoldo, and Schellhammer, Paul F.: BCG Therapy for High Risk

- Stage T₁ Superficial Bladder Cancer. Presented at the Annual American Urological Association Meeting New Orleans, May 1990
- Eure, Gregg R.: Bladder Neck Obstruction. Presented Mid-Atlantic Section, American Urological Association, September, 1990
- Schellhammer PF, Eure GR: The role of radical cystectomy in the management of high grade superficial bladder cancer (Pa, P1, P1S, and P2). J Urol 1991 Nov;146(5):1378-9
- Eure, Gregg R., Cundiff, Maria R., and Schellhammer, Paul F.: BCG Therapy for High Risk Stage T₁ Superficial Bladder Cancer. The Journal of Urology, Vol. 147(2), 376-379, February, 1992
- Benge, Bruce N., Eure, Gregg R., and Winslow, Boyd H.: Acute Bilateral Testicular Torsion in the Adolescent. The Journal of Urology, Vol 148(1), 134, July 1992.
- Miller, E. Bradley, Eure, Gregg R., and Schellhammer, Paul F.: Upper tract Transitional Cell Carcinoma in Patients Treated with BCG; Annual Meeting May 1992, Mid-Atlantic Section, American Urological Association September 1992
- Miller, E. Bradley., Eure, Gregg R., Schellhammer, Paul F.: Upper Tract Transitional Cell Carcinoma Following the Treatment of Superficial Bladder Cancer with BCG. Urology, Vol. 42(1), 26-30, July 1993.
- Jordan GH, Whelan TV, Horstman WG, Tynes WV II, Robey EL, Eure, GR, Stecker JF Jr, Winslow BH, Fabozzi SF, Schellhammer PF, and Lynch DF Jr.: Urology/Urinary System. The Pathophysiologic Basis of Surgery, Chapter 23, pp. 581-601. Second Edition, Editor, J. Patrick Leary, Baltimore: Williams & Wilkins, 1996
- Eure, Gregg R., Schellhammer, Paul F.: Hormone Refractory Prostate Cancer. Topics in Clinical Urology: Medical and Surgical Management of Prostate Cancer, 1996.
- Albala DM, Turk TM, Fulmer BR, Koleski F, Andriole G, Davis BE, Eure GR, Kabalin JN, Lingeman J, Nuzzarello J, Sundaram C: Periurethral transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia: an interim 1-year safety and efficacy analysis using the Thermatrx TMx-2000. Tech Urol. 2000 Dec;6(4):288-93
- Albala DM, Fulmer BR, Turk TM, Koleski F, Andriole G, Davis BE, Eure GR, Kabalin JN, Lingeman JE, Nuzzarello J, Sundaram C: Office Based Transurethral Microwave Thermotherapy Using The TherMatrx TMx-2000. J Endourol 2002 Feb;16(1):57-61
- Albala DM, Nuzzarello J, Kabalin JN, Andriole G, Eure GE, Davis BE, Lingeman JE: Transurethral Microwave Thermotherapy (TUMT) Using The Thermatrx TMX-2000: A Quantitative Assessment Of Patient Tolerance. Abstract #1165, American Urological Association Annual Meeting, May 25-30, 2002, Orlando, Florida
- Albala DM, Andriole G, Davis BE, Eure GR, Kabalin JN, Lingeman JE, Nuzzarello J, and Risk I: Transurethral Microwave Thermotherapy (TUMT) Using The Thermatrx TMX-2000: Durability Exhibited In A Study Comparing TUMT With A SHAM Procedure In Patients With Benign Prostatic Hyperplasia (BPH), Abstract #1746, American Urological Association Annual Meeting, Chicago, IL, April 26-May 1, 2003

Eure, Gregg R.: Urology Times. BPH treatment Device may improve sexual function April 2005

Albala DM, Andriole G, Davis BE, Eure GR, Kabalin JN, Lingeman JE, Nuzzarello J, and Risk I:
Transurethral Microwave Thermotherapy (TUMT) Using The Thermatrix TMX-2000: Durability
For Treatment of Benign Prostatic Hyperplasia: Five Year Follow-Up Of Multicenter
Randomized Pivotal Trial October 2005

Eure, Gregg R.:PDR Disease Management Guide. Management of Patients with Benign Prostatic
Hyperplasia 2005

Eure GR, Lamont J, Plante M, Snyder, J:
Transurethral Microwave Thermotherapy (TUMT) Evaluation of the Thermatrix TMX-2000 Short
Treatment Protocol Procedural Tolerability and Short Term Efficacy in Patients with Benign
Prostatic Hyperplasia (BPH):Thermatrix EAU Abstract October 2006

Eure GR, Bepple J, Barone B:
A Randomized, Placebo-Controlled, Double-Blind Study of the use of Dutasteride for improving
peri-operative Outcomes of Photoselective Vaporization of the Prostate (DOP Trial) April, 2007

Eure, Gregg R: PDR Disease Management Guide: Management of Patients with Benign Prostatic
Hyperplasia 2008

OTHER PUBLICATIONS

News Article for The Beacon, a Virginian Pilot Supplement regarding prostate screenings. September
1998

“Urology Now”, Newsletter for referring physicians in the Virginia Beach area. October 1996.